When applied in the treatment of HER2-positive GC (Figure 5), the HER2 antigen-specific activation of expanded CAR-T cells can effectively eradicate HER2-positive GC cells from patients, enhancing treatment efficacy and prognosis (11). This evidence concerns the gene ERBB2 and gastric cancer.